Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance
about
Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspectiveAcquired and Transmitted Multidrug Resistant Tuberculosis: The Role of Social DeterminantsPrevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis.Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania.Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012-2014Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis.Multidrug-resistant tuberculosis patients lost to follow-up: self-reported readiness to restart treatment.Baseline Predictors of Treatment Outcomes in Children With Multidrug-Resistant Tuberculosis: A Retrospective Cohort Study.Impact of fluoroquinolone use on mortality among a cohort of suspected drug-resistant tuberculosis patients.Immunoassay Analysis of Kanamycin in Serum Using the Tobramycin Kit.Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China.Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000-2015.Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.Determining Genotypic Drug Resistance by Ion Semiconductor Sequencing With the Ion AmpliSeq™ TB Panel in Multidrug-Resistant Mycobacterium tuberculosis Isolates.Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis.
P2860
Q28074085-405A8FED-3A86-4F62-B15E-591F987E08DDQ28552456-37942189-A6A2-4382-8C9E-E2EE1C59BEECQ30252340-34F4900C-A7BA-410C-AC28-1EF729125A7DQ30274875-BE55C227-5DD5-4411-98C1-04766EF094D8Q36617035-9D30C7BA-CAE9-4711-A8CB-25F3868AA0F0Q37358689-4FA2BCD6-3F98-4EDC-A818-1C18B05343A2Q37675764-E2CD8842-BEE2-4E5B-9FF9-0C7DF54F7DC6Q38923981-7831E46C-6838-4B62-95AB-994A810F450BQ39560188-AAA4E573-A85C-4192-B424-06A8B2FCC550Q40224832-C72B4C86-5F0E-4429-A531-5D9FAB7A2A07Q41817586-4BBE9C38-77F2-4A65-B625-A299FEE7739DQ50044320-562B69A8-6EBF-455A-A81E-804BBEFDDEA2Q50317039-D1825DA0-2113-4734-AD26-0ED121579BB4Q53698038-CB0C5A01-B554-47DF-88DB-0CCE11FEFCD2Q53699080-63599487-B1FB-4077-B01E-61016F14099DQ55208580-40E72E76-44F1-4693-AD42-3EFD3105046B
P2860
Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Multidrug-Resistant Tuberculos ...... ed Second-Line Drug Resistance
@ast
Multidrug-Resistant Tuberculos ...... ed Second-Line Drug Resistance
@en
type
label
Multidrug-Resistant Tuberculos ...... ed Second-Line Drug Resistance
@ast
Multidrug-Resistant Tuberculos ...... ed Second-Line Drug Resistance
@en
prefLabel
Multidrug-Resistant Tuberculos ...... ed Second-Line Drug Resistance
@ast
Multidrug-Resistant Tuberculos ...... ed Second-Line Drug Resistance
@en
P2093
P2860
P356
P1476
Multidrug-Resistant Tuberculos ...... ed Second-Line Drug Resistance
@en
P2093
Allison Taylor Walker
Andra Cirule
Angela Song-En Huang
Beverly Metchock
Boris Y Kazennyy
Carmen Contreras
Carmen Suarez
Chang-Ki Kim
Charlotte Kvasnovsky
Doosoo Jeon
P2860
P304
P356
10.1093/CID/CIV910
P407
P577
2015-10-27T00:00:00Z